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Vardenafil is a novel PDE-5 blocker whit known vasodila-
tory properties via enhanced cGMP accumulation. In the
present pre-clinical study, we investigated the effects of
vardenafil pretreatment on myocardial and endothelial
function in an experimental model of cardioplegic arrest
and extracorporal circulation.
Twelve anesthetized dogs, underwent hypothermic cardi-
opulmonary bypass. 6 digs received vardenafil (30 μg/kg)
prior initiation of cardiopulmonary bypass. After 60 min-
utes of hypothermic cardiac arrest, reperfusion was
started. Left ventricular end-systolic pressure volume rela-
tionship (Ees) was measured by a combined pressure-vol-
ume-conductance catheter at baseline and after 60
minutes of reperfusion. Left anterior descendent coronary
blood flow (CBF) and endothelium-dependent vasodila-
tation to acetylcholine (ACH) were determined.
The admimistration of vardenafil led to a significantly bet-
ter recovery (given as percent of baseline) of Ees 75 ± 5 %
vs. 49 ± 5 %, p < 0.05. CBF and was also significantly
higher in the Vardenafil group (58 ± 12 vs. 21 ± 3, ml/
min, p < 0.05). ACH resulted in a significantly higher
increase in CBF (80 ± 6% vs. 29 ± 5%, p < 0.05) in the Var-
denafil group.
Application of vardenafil improves myocardial and
endothelial function after cardiopulmonary bypass with
hypothermic cardiac arrest.
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